idarubicin hydrochloride

P2, N=60, Completed, City of Hope Medical Center | Active, not recruiting --> Completed

Induction chemotherapy (cytarabine and idarubicin) initially achieved remission, but subsequent relapses led to the use of venetoclax and 5-azacytidine, which again resulted in remission. This is the first report that molecularly characterizes the HMBOX1::JAK2 fusion in a de novo AML patient. The identification of this novel alteration adds to the growing and heterogeneous molecular landscape of AML and suggests a potential new avenue for targeted therapy.

Although pleural myeloid sarcoma is extremely rare, it must be included in the differential diagnosis for unexplained solid pleural masses, particularly when accompanied by pleural effusion. Upon diagnosis, comprehensive staging investigations, including bone marrow biopsy and flow cytometry, must be performed immediately. The successful management of such complex cases relies on the close collaboration of a multidisciplinary team, including radiologists, pathologists, hematologists, and thoracic surgeons. Radiologists identify atypical imaging features, pathologists confirm the diagnosis through precise immunophenotyping, and ultimately, hematologists formulate and execute the correct treatment plan.

P2, N=100, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027

P3, N=100, Recruiting, Federal Research Institute of Pediatric Hematology, Oncology and Immunology

P2, N=240, Recruiting, Guangdong Provincial People's Hospital | Not yet recruiting --> Recruiting

P1/2, N=53, Active, not recruiting, University of Southern California | Trial primary completion date: Oct 2025 --> Oct 2026

P2, N=102, Not yet recruiting, OHSU Knight Cancer Institute

Drug prediction and molecular docking identified chlorendic acid, idarubicin, PHA-848,125, and tosedostat as potential activators of the OAS family due to their strong binding affinity. Conversely, GW842166, NSC 23,766, and metolazone showed high binding affinity for OASL and may inhibit its expression. In summary, The OAS gene family, associated with poor prognosis in gastric cancer, promotes tumour progression and represents a promising therapeutic target.

P2, N=22, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Oct 2030 --> Sep 2029

This retrospective multicenter study analyzed the clinical outcomes and prognostic factors for relapse in 286 Korean patients treated with ATRA and idarubicin-based chemotherapy protocols between 2002 and 2024...Moreover, our findings indicate that post-consolidation MRD is the most significant predictor of relapse, emphasizing the need for molecular profiling and longitudinal monitoring. Future prospective studies should validate these prognostic markers and refine personalized therapeutic approaches for APL.

P1, N=200, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Oct 2024 --> Oct 2026